Springer Medicine

Sarcopenic obesity is an emerging risk factor for CVD, particularly in older adults. Optimizing its treatment and management will become increasingly important as the global population ages.

Lung transplantation is the definitive treatment for end-stage respiratory disease, but complications can occur. This review highlights the key imaging and clinical features that radiologists and clinicians need to be aware of to ensure optimal post-transplant care.

25% of gliomas in adolescents and young adults are pediatric-type LGG. Should treatment in this older age group be the same as in children?

SELECT study findings indicate that semaglutide produces significant long-term weight loss in people with cardiovascular disease and overweight or obesity but not diabetes.

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.